Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novavax Says COVID-19 Vaccine 90% Effective; Plans to Seek Regulatory Authorization in Third Quarter

06/14/2021 | 09:32am EDT


© MT Newswires 2021
All news about NOVAVAX, INC.
07/27Dassault Systemes lifts 2021 outlook on surging software sales
RE
07/22INSIDER TRENDS : Novavax Sees 90 Days of Insider Buying Trend Scaling Back with ..
MT
07/20EU begins real-time review of Sanofi-GSK COVID-19 vaccine
RE
07/13S.Korea COVID-19 vaccine rollout grinds to halt as new cases spike
RE
07/12SINOPHARM : Sinovac to Supply COVID-19 Vaccines to COVAX
MT
07/09New Fujifilm CEO focuses on drug ingredients unit after Avigan stumbles
RE
07/06NOVAVAX : to Host Conference Call to Discuss Second Quarter Financial Results an..
PR
07/05S.Korea in talks with mRNA vaccine makers to make up to 1 bln doses -govt off..
RE
07/04S.Korea in talks with mRNA vaccine makers to make up to 1 bln doses -govt off..
RE
07/02MARKET CHATTER : Taiwan Plans to Obtain Novavax COVID-19 Vaccine via COVAX
MT
More news
Financials (USD)
Sales 2021 2 163 M - -
Net income 2021 -458 M - -
Net cash 2021 79,2 M - -
P/E ratio 2021 -24,1x
Yield 2021 -
Capitalization 13 285 M 13 285 M -
EV / Sales 2021 6,11x
EV / Sales 2022 2,13x
Nbr of Employees 792
Free-Float 98,7%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 179,33 $
Average target price 249,60 $
Spread / Average Target 39,2%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
John J. Trizzino CFO, EVP, Chief Commercial & Business Officer
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.60.82%13 285
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 837